Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ENGN | Common Shares | Award | $6.45M | +645K | +184.97% | $10.00 | 994K | Feb 20, 2024 | See Notes | F1, F7, F8 |
transaction | ENGN | Common Shares | Award | $1.55M | +155K | +184.97% | $10.00 | 239K | Feb 20, 2024 | See Notes | F2, F7, F8 |
holding | ENGN | Common Shares | 1.34M | Feb 20, 2024 | See Notes | F3, F7, F8 | |||||
holding | ENGN | Common Shares | 44.6K | Feb 20, 2024 | See Notes | F4, F7, F8 | |||||
holding | ENGN | Common Shares | 1.08M | Feb 20, 2024 | See Notes | F5, F7, F8 | |||||
holding | ENGN | Common Shares | 153K | Feb 20, 2024 | See Notes | F6, F7, F8 |
Id | Content |
---|---|
F1 | These securities are held by Lumira Ventures IV, L.P. ("Lumira IV"). |
F2 | These securities are held by Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"). |
F3 | These securities are held by Lumira Ventures III, L.P. ("Lumira III"). |
F4 | These securities are held by Lumira Ventures III (International), L.P. ("Lumira III Int'l"). |
F5 | These securities are held by Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"). |
F6 | These securities are held by Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). |
F7 | Mr. Brunk is an executive officer of certain entities controlling and/or managing the Lumira Entities. Mr. Brunk disclaims beneficial ownership of the Common Shares held by the Lumira Entities, except to the extent of his pecuniary interest therein, if any. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc. ("Lumira Mgmt"). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. (Continued in following footnote). |
F8 | (Continued from prior footnote). Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any. |